Could a new biomarker improve kidney transplant outcomes for patients?

Imagine receiving a kidney transplant and having a better chance at a successful recovery. This study is enrolling 800 adult first-time kidney transplant recipients to evaluate a new biomarker, the HLA-DR/DQ molecular mismatch score. This score could help doctors predict the risk of complications after the transplant. After six months, 300 eligible participants will be randomly assigned to either receive abatacept, a new treatment, or standard care. The goal is to see if switching from Tacrolimus, a common medication, to abatacept can improve kidney function and overall quality of life while still preventing rejection of the new kidney. This research is crucial because it could lead to better outcomes for patients, helping them enjoy a healthier life after transplant.